Stay updated with breaking news from Gamida Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- DelveInsight's Paroxysmal Nocturnal Hemoglobinuria Market Insights report includes a comprehensive understanding of current treatment...
Treatments for blood cancer and rare diseases are the target markets, but investors are well aware of the challenges that await after approval is received.
In a report released today, Gil Blum from Needham reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price...
14.11.2022 - Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ...
Gamida Cell Ltd. (NASDAQ:NASDAQ:GMDA) Q3 2022 Results Conference Call November 14, 2022 8:00 AM ETCompany ParticipantsHeather DiVecchia - Director of IR & Corporate...